TICKERNERD
Menu
HNGEHNGEHealthcare · Health Information Services

HNGE Stock Forecast: Hinge Health, Inc. Price Predictions for 2026-2027

Last close, 13 Oct 2026
$105
+0.31% on the day

The 17 Wall Street analysts covering Hinge Health, Inc. hold a median 12-month price target of $110 — +4.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 12 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$8.3B
Ticker Nerd rank
80 / 100
Median analyst target
$110
Analysts covering
17
Revenue$212.8M+53.0% y/y
Operating income$40.4M
Net income$43.7M
Free cash flow$99.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.9%
1M
+18.7%
YTD
+126.4%
1Y
+108.6%
From 52W high
0.0%
From 52W low
+237.3%
$31
$105
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HNGE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Hinge Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
91
Momentum
85
Accruals
82
Quality
79
Issuance
67
Revisions
66
Value
40
Volatility
23
Size
17

Growth (91): Sales and profits are climbing, and climbing faster than before.

Volatility (23): The share price moves around a lot.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HNGE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HNGE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26HNGEHigh $140Median $110Low $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $90Median $110High $140

The green dot is the last close — the median target sits +4.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 Sept 2026NeedhamMaintainsBuy$97 → $115
22 Sept 2026BairdMaintainsNeutral—
22 Sept 2026BairdMaintainsNeutral$85 → $90
8 Sept 2026StifelMaintainsBuy$96 → $115
8 Sept 2026StifelMaintainsBuy—
11 Aug 2026Truist SecuritiesMaintainsBuy$85 → $112
11 Aug 2026Truist SecuritiesMaintainsBuy—
5 Aug 2026BarclaysMaintainsOverweight$97 → $100
5 Aug 2026BarclaysMaintainsOverweight—
5 Aug 2026CitizensMaintainsMarket Outperform$96 → $107
5 Aug 2026CitizensMaintainsMarket Outperform—
5 Aug 2026Evercore ISI GroupMaintainsOutperform$100 → $105
5 Aug 2026Evercore ISI GroupMaintainsOutperform—
5 Aug 2026NeedhamMaintainsBuy$76 → $97
5 Aug 2026NeedhamMaintainsBuy—
5 Aug 2026RBC CapitalMaintainsOutperform—
5 Aug 2026RBC CapitalMaintainsOutperform$75 → $110
5 Aug 2026Wells FargoMaintainsOverweight$90 → $103
5 Aug 2026Wells FargoMaintainsOverweight—
27 July 2026CitizensMaintainsMarket Outperform$80 → $96

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HNGE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HNGE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Oct 2026, Hinge Health, Inc. returned +108.6% against +18.6% for the S&P 500, dividends included.

HNGE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26HNGES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HNGE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−7.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Hinge Health, Inc. (HNGE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.8×

Cheaper than 23% of US stocks

Price / sales
11.5×

Cheaper than 13% of US stocks

Price / book
23.9×

Cheaper than 4% of US stocks

EV / EBITDA
82.8×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
53.0%

Higher than 87% of US stocks

Earnings growth (YoY)
53.0%

Higher than 75% of US stocks

Gross margin
86.4%

Higher than 95% of US stocks

Operating margin
19.0%

Higher than 78% of US stocks

Net margin
15.1%

Higher than 78% of US stocks

Returns & dividend
Return on equity
30.4%

Higher than 88% of US stocks

Return on assets
7.7%

Higher than 87% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Hinge Health, Inc. (HNGE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Hinge Health, Inc. has a market value of $8.3B and an enterprise value of $7.9B.

  • Revenue in the twelve months to 30 June 2026: $720.1M. The latest quarter grew 53.0% year on year.

  • Net income over the same four quarters: $109.1M, a 15.1% net margin.

  • Diluted earnings per share, trailing twelve months: $1.28.

  • Free cash flow in the twelve months to 30 June 2026: $283.9M, after $6.2M of capital spending.

  • Shares outstanding: 80.2M.

  • Trailing P/E: 33.8×; forward P/E: 33.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Hinge Health, Inc. employs 1,437 people — $501K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

HNGE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
HNGEHinge Health, Inc.$8.3B
80
HQYHealthEquity, Inc.$7.9B
94
DOCSDoximity, Inc.$5.6B
60
TEMTempus AI, Inc.$12.2B
24
BTSGBrightSpring Health Services, Inc.$12.2B
90
WAYWaystar Holding Corp.$5.1B
36
HTFLHeartFlow, Inc.$4.3B
48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Hinge Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HNGE news & analysis

Hinge Health to announce third quarter 2026 financial results on November 2, 2026

Business Wire · 5 Oct 2026neutral

Hinge Health, Inc. announced it will report its financial results for the quarter ended September 30, 2026, after U.S. markets close on Monday, November 2, 2026. The company will also host an earnings conference call at 1:30 p.m. Pacific Time that same day, with a live audio webcast available on its Investor Relations page.

Why it matters — This announcement gives HNGE watchers a confirmed date and time for the upcoming quarterly earnings report and conference call, which they can expect to monitor for the company's latest results and guidance.

3 Healthcare Stocks Showing Why the Sector Still Has Momentum

MarketBeat · 28 Sept 2026positive

MarketBeat reports that the healthcare sector has performed well so far in 2026, driven by continued interest in GLP-1 medications and AI applications that accelerate drug discovery. Potential mergers and acquisitions, stemming from a major patent cliff facing big pharmaceutical companies, could create opportunities for new firms to stand out.

Why it matters — As a healthcare company, Hinge Health could benefit from the sector's overall momentum and the favorable conditions noted for firms in the space.

Reasons to Hold Hinge Health Stock in Your Portfolio for Now

Zacks Investment Research · 21 Sept 2026positive

Hinge Health has shown strong revenue growth and raised its 2026 outlook, while expanding into Migraine and GI care, which supports its growth prospects despite investment-related pressures. The article frames these developments as reasons to hold the stock for now.

Why it matters — HNGE watchers would care because this signals sustained momentum through revenue gains, an upgraded forward outlook, and new care-line expansion, even amid near-term investment costs.

Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead

CNBC · 8 Sept 2026neutral

CNBC's Jim Cramer said investors are overly focused on AI data-center stocks and should look to other areas of the market, highlighting aerospace, fintech, health care, and energy stocks as compelling opportunities.

Why it matters — The mention of health care as an area of opportunity could draw investor attention to the sector where Hinge Health operates.

Hinge Health Director Kristina Leslie Sells 1,200 Shares for $105,876

The Motley Fool · 4 Sept 2026neutral

Hinge Health Director Kristina Leslie sold 1,200 shares of the company for $105,876, reducing her directly held position by 4% while retaining a multi-million dollar stake. The transaction involved only directly held shares, with no indirect holdings reported.

Why it matters — HNGE watchers would note insider selling activity as it can signal a director's view on the stock, though the relatively small reduction and retained large stake moderate its significance.

FAQ

Frequently asked questions about HNGE stock

What is the HNGE stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Hinge Health, Inc. have a median 12-month price target of $110, with estimates ranging from $90 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HNGE stock a buy right now?

Of the 17 analysts covering Hinge Health, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hinge Health, Inc. 80 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HNGE?

As at 12 Oct 2026, Hinge Health, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).

Will HNGE stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +4.6% from the last close, and Ticker Nerd's factor model ranks Hinge Health, Inc. 80 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HNGE stock forecast for 2030?

No analyst covering Hinge Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HNGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $140 over the next 12 months.

How has HNGE stock performed over the past year?

Hinge Health, Inc. returned +108.6% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Hinge Health, Inc. do?

Hinge Health, Inc. Class A Common Stock represents ownership in Hinge Health, a digital healthcare company focused on musculoskeletal care.

What is the latest news on HNGE?

The most recent item we track (Business Wire, 5 Oct 2026): "Hinge Health to announce third quarter 2026 financial results on November 2, 2026". Hinge Health, Inc. announced it will report its financial results for the quarter ended September 30, 2026, after U.S. markets close on Monday, November 2, 2026. The company will also host an earnings conference call at 1:30 p.m. Pacific Time that same day, with a live audio webcast available on its Investor Relations page.

Company

About Hinge Health, Inc.

Hinge Health, Inc. Class A Common Stock represents ownership in Hinge Health, a digital healthcare company focused on musculoskeletal care. The company provides software-driven solutions for joint and muscle health, combining virtual care, clinician support, and digital programs designed to help people manage acute injury, chronic pain, and recovery from surgery. Its platform is used by employers, health plans, and other healthcare payers seeking scalable care delivery for members with MSK needs. Hinge Health also incorporates technologies such as artificial intelligence, motion tracking, and connected wearable devices to support personalized care experiences. Based in San Francisco, Hinge Health serves a specialized segment of the healthcare technology market centered on prevention, treatment, and management of musculoskeletal conditions.

CEO Mr. Daniel A. Perez · 1,437 employees · United States · https://www.hingehealth.com